{
    "id": "342a1f23-2fe7-0483-e063-6394a90a8d49",
    "indications": {
        "text": "potassium citrate citrate salt potassium indicated management : \u2022 renal tubular acidosis ( rta ) calcium stones ( 1.1 ) \u2022 hypocitraturic calcium oxalate nephrolithiasis etiology ( 1.2 ) \u2022 uric acid lithiasis without calcium stones ( 1.3 )",
        "doid_entities": [
            {
                "text": "renal tubular acidosis (DOID:14219)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_14219"
            },
            {
                "text": "calcium oxalate nephrolithiasis (DOID:0080652)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0080652"
            },
            {
                "text": "nephrolithiasis (DOID:585)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_585"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "objective : restore normal urinary citrate ( greater 320 mg/day close normal mean 640 mg/day possible ) , increase urinary ph level 6.0 7.0 . \u2022 severe hypocitraturia ( urinary citrate < 150 mg/day ) : therapy initiated 60 meq per day ; dose 30 meq two times per day 20 meq three times per day meals within 30 minutes meals bedtime snack ( 2.2 ) \u2022 mild moderate hypocitraturia ( urinary citrate > 150 mg/day ) : therapy initiated 30 meq per day ; dose 15 meq two times per day 10 meq three times per day meals within 30 minutes meals bedtime snack ( 2.3 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "potassium citrate extended-release tablets usp 15 meq uncoated , pale yellow colored , caplet shaped , bi-convex , debossed 's408 ' one side plain side , supplied bottles : ndc 72162-2478-1 : 100 tablets bottle storage : store tight container 20\u00b0\u201325\u00b0c ( 68\u00b0\u201377\u00b0f ) , excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . repackaged/relabeled : bryant ranch prepack , inc. burbank , ca 91504",
    "adverseReactions": "potassium citrate extended-release tablets contraindicated : \u2022 patients hyperkalemia ( conditions predisposing hyperkalemia ) , rise serum potassium concentration may produce cardiac arrest . conditions include : chronic renal failure , uncontrolled diabetes mellitus , acute dehydration , strenuous physical exercise unconditioned individuals , adrenal insufficiency , extensive tissue breakdown potassium-sparing agent ( triamterene , spironolactone amiloride ) . \u2022 patients cause arrest delay tablet passage gastrointestinal tract , suffering delayed gastric emptying , esophageal compression , intestinal obstruction stricture , taking anticholinergic medication . \u2022 patients peptic ulcer disease ulcerogenic potential . \u2022 patients active urinary tract infection ( either urea-splitting organisms , association either calcium struvite stones ) . ability potassium citrate extended\u2013release tablets increase urinary citrate may attenuated bacterial enzymatic degradation citrate . moreover , rise urinary ph resulting potassium citrate therapy might promote bacterial growth . \u2022 patients renal insufficiency ( glomerular filtration rate less 0.7 ml/kg/min ) , danger soft tissue calcification increased risk development hyperkalemia .",
    "ingredients": [
        {
            "name": "CARNAUBA WAX",
            "code": "R12CBM0EIZ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_73702"
        },
        {
            "name": "STEARIC ACID",
            "code": "4ELV7Z65AP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "POTASSIUM CITRATE",
            "code": "EE90ONI6FF",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09125"
        }
    ],
    "organization": "Bryant Ranch Prepack",
    "name": "POTASSIUM CITRATE",
    "effectiveTime": "20250502",
    "indications_original": "Potassium citrate is a citrate salt of potassium indicated for the management of: \u2022 Renal tubular acidosis (RTA) with calcium stones (1.1) \u2022 Hypocitraturic calcium oxalate nephrolithiasis of any etiology (1.2) \u2022 Uric acid lithiasis with or without calcium stones (1.3)",
    "contraindications_original": "Objective: To restore normal urinary citrate (greater than 320 mg/day and as close to the normal mean of 640 mg/day as possible), and to increase urinary pH to a level of 6.0 to 7.0. \u2022 Severe hypocitraturia (urinary citrate < 150 mg/day): therapy should be initiated at 60 mEq per day; a dose of 30 mEq two times per day or 20 mEq three times per day with meals or within 30 minutes after meals or bedtime snack (2.2) \u2022 Mild to moderate hypocitraturia (urinary citrate >150 mg/day): therapy should be initiated at 30 mEq per day; a dose of 15 mEq two times per day or 10 mEq three times per day with meals or within 30 minutes after meals or bedtime snack (2.3)",
    "warningsAndPrecautions_original": "Potassium citrate extended-release tablets USP 15 mEq are uncoated, pale yellow colored, caplet shaped, bi-Convex, debossed with 'S408' on one side and plain on the other side, supplied in bottles as:\n                  \n                     NDC 72162-2478-1: 100 Tablets in a BOTTLE\n                  \n                  \n                  Storage: Store in a tight container at 20\u00b0\u201325\u00b0C (68\u00b0\u201377\u00b0F), Excursions permitted between 15\u00b0 and 30\u00b0C (59\u00b0 and 86\u00b0F) [See USP controlled room temperature].\n                  \n                  Repackaged/Relabeled by:\n  \nBryant Ranch Prepack, Inc.\n  \nBurbank, CA 91504",
    "adverseReactions_original": "Potassium citrate extended-release tablets are contraindicated:\n                  \u2022 In patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride).\n                  \u2022 In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication.\n                  \u2022 In patients with peptic ulcer disease because of its ulcerogenic potential.\n                  \u2022 In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of Potassium citrate extended\u2013release tablets to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth.\n                  \u2022 In patients with renal insufficiency (glomerular filtration rate of less than 0.7 ml/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia.",
    "drug": [
        {
            "name": "POTASSIUM CITRATE",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09125"
        }
    ]
}